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Abstract
Background: Evolutionarily conserved RFX transcription factors (TFs) regulate their target genes through a DNA
sequence motif called the X-box. Thereby they regulate cellular specialization and terminal differentiation. Here, we
provide a comprehensive analysis of all the eight human RFX genes (RFX1–8), their spatial and temporal expression
profiles, potential upstream regulators and target genes.
Results: We extracted all known human RFX1–8 gene expression profiles from the FANTOM5 database derived
from transcription start site (TSS) activity as captured by Cap Analysis of Gene Expression (CAGE) technology. RFX
genes are broadly (RFX1–3, RFX5, RFX7) and specifically (RFX4, RFX6) expressed in different cell types, with high
expression in four organ systems: immune system, gastrointestinal tract, reproductive system and nervous system.
Tissue type specific expression profiles link defined RFX family members with the target gene batteries they
regulate. We experimentally confirmed novel TSS locations and characterized the previously undescribed RFX8 to be
lowly expressed. RFX tissue and cell type specificity arises mainly from differences in TSS architecture. RFX transcript
isoforms lacking a DNA binding domain (DBD) open up new possibilities for combinatorial target gene regulation.
Our results favor a new grouping of the RFX family based on protein domain composition. We uncovered and
experimentally confirmed the TFs SP2 and ESR1 as upstream regulators of specific RFX genes. Using TF binding
profiles from the JASPAR database, we determined relevant patterns of X-box motif positioning with respect to
gene TSS locations of human RFX target genes.
Conclusions: The wealth of data we provide will serve as the basis for precisely determining the roles RFX TFs play
in human development and disease.
Keywords: Cell differentiation, Cilia, Spermatogenesis, Immune cell proliferation, Neuronal development, Cell cycle control,
Tumor suppression
Background
RFX (Regulatory Factor binding to the X-box) transcription
factors (TFs) share and are defined by a conserved, special-
ized winged-helix type DNA binding domain (DBD) [1].
RFX genes have been identified in all animals within the
Unikont branch of eukaryotes, which excludes algae, plants
and various protozoan branches [2]. Metazoan genomes en-
code one to several RFX genes. C. elegans possesses one,
Drosophila has two [3, 4], mammals have eight and – due to
genome duplication – fishes have nine RFX genes [2, 5–10].
Human RFX1–7 have previously been described [9], while
RFX8 (ENSG00000196460, www.ensembl.org) has not been
characterized.
In different organisms, RFX TFs have been shown to
regulate genes involved in various and seemingly disparate
cellular and developmental processes [7] like the cell cycle
and DNA repair [11, 12], or aspects of cellular differenti-
ation, like the functional maturation of cells of the immune
response [13] and the development of cilia on the surface
of polarized cells [14–16]. As a consequence of these roles
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in development, mutations in RFX genes can lead to severe
disease states. Mutations in RFX5 cause autosomal reces-
sive Bare Lymphocyte Syndrome (OMIM #209920), charac-
terized by severe combined immunodeficiency due to
failure in HLA expression. Mutations in RFX6 cause auto-
somal recessive Mitchell-Riley Syndrome, characterized by
neonatal diabetes and malformations of the gut (OMIM
#615710). Rfx mutant mice exhibit a plethora of mild to
fatal phenotypes, ranging from male sterility [17] to brain
abnormalities [18]. These phenotypes are often attributed
to cilia dysfunction [17, 19–21]. Of note, many human
ciliopathy genes are strongly assumed to be RFX TF targets,
given that their orthologs have been shown to be RFX TF
targets in several different organisms, ranging from C. ele-
gans to mouse [22–24].
In addition to the DBD, RFX TFs may contain other con-
served domains like activation (AD) and dimerization
(DIM) domains and the domains B and C of unknown
function [7, 9]. The RFX DBD recognizes an imperfect
inverted repeat sequence, the X-box motif, to which it binds
[1]. RFX TF binding to the X-box motif has repeatedly been
demonstrated by using methods ranging from in vitro bind-
ing studies, in vivo expression and mutation analyses to
SELEX and ChIP sequencing approaches [8, 25–28]. Com-
bined, these approaches led to the discovery of large batter-
ies of RFX target genes [16].
By contrast, very little is known about upstream regu-
lators of RFX genes. So far only a few studies in mice,
zebrafish and flies have identified TFs of the bHLH class,
Neurog3 and Atonal, as well as the homeobox protein
Noto as upstream regulators of RFX genes [29–31]. In
the yeast S. cerevisiae an upstream phosphorylation cas-
cade controls expression of the RFX gene Crt1 [32].
In this study – using extensive analysis of data from the
FANTOM5 database followed by experimental validations
– we present an in-depth characterization of the entire
human RFX gene family (RFX1–8), including the previ-
ously undescribed RFX8 and RFX transcript isoforms that
encode TFs without DBD. We provide an updated group-
ing of human RFX TFs and show that RFX functional do-
main composition is independent of expression profile.
Our exhaustive analysis of RFX expression in many differ-
ent human tissues and cell types suggests that RFX tissue
and cell type specificity arises mainly from differences in
TSS architecture and not from different transcript iso-
forms. We determined with high precision the positioning
of X-box motifs with respect to TSS locations of human
RFX target genes. Using cluster analysis based on tissue
and cell type specific expression profiles we link defined
RFX family members with the target gene batteries they
regulate. Further, we provide a first list of candidate up-
stream regulators of human RFX genes. The wealth of
data we provide will serve as the basis for future studies of
the role of RFX TFs in human development and disease.
Results
Expression of human RFX genes in different tissue types
Detailed expression profiles of the human RFX1–8 genes
have not been described. We used data from the FAN-
TOM5 database that is based on experimental expression
profiling by CAGE technology across a wide spectrum of
human biological samples. The expression level of a given
CAGE TSS location is defined by an arbitrary unit, tags
per million (TPM) [33]. We extracted 37 CAGE TSS loca-
tions for RFX1–8 from the FANTOM 5database and
shortlisted these to 30 TSS locations by merging those
which are in close proximity to each other and have simi-
lar expression profiles (cf. Methods). We then named
these 30 TSS locations alphabetically, whereby promoter
A (pA) is the highest expressed TSS. Expression of each
RFX TSS is described in detail for human tissues, primary
cells and cell lines (Additional file 1). The wealth of bio-
logical samples allows classifying the expression profiles
for human RFX1–8 in different cell types.
A given RFX TSS location is considered as being
expressed broadly if it is expressed at TPM > 5 in a large
number and variety of tissues (n > 10). Conversely, a
given RFX TSS location is considered as being expressed
specifically if it is expressed at TPM> 5 in a small num-
ber of tissues of the same organ (n < 10). We found most
TSS locations of RFX1–3, 5 and 7 to be expressed
broadly in many tissue types whereas the TSS locations
of RFX4 and RFX6 are all expressed in specific tissue
types. pA@RFX4 is highly specific in brain and spinal
cord tissues, while pB and pC@RFX4 are highly specific
in testis. RFX6 TSS locations are all specifically
expressed in the gastrointestinal tract (GI) (Additional
file 2). We performed hierarchical clustering of the 30
RFX TSS locations based on their expression values
(TPM) across 135 human tissue samples. Thereby we
identified four major tissue clusters, namely immune
system [34], gastrointestinal tract [35, 36], testis [37] and
brain and spinal cord [18, 38–41], and two minor clus-
ters, namely uterus and lung [42] (Additional file 2).
The expression of RFX8 is very low, making it the most
elusive member of the human RFX family that has hitherto
avoided detection. Here we identified RFX8 TSS locations
with highest expressions in some tissues of the immune
system (pA, pC, pD) and the gastrointestinal tract (pB, pE).
However, the tissue expression values for pC, pD and pE
were hard to distinguish from background noise (TPM< 1).
In primary cells and cell lines, RFX8 TSS locations had
higher expression values, with the most prominent expres-
sion in a Schwannoma cell line (Additional file 2).
Connecting TSS expression profiles to protein-coding
transcript isoforms
FANTOM5 data allowed us to determine TSS locations and
expression profiles. In order to connect the 30 RFX TSS
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locations described above to known transcript isoforms, we
set a maximum distance limit of 50 nt between the TSS lo-
cation and the nearest Ensembl protein-coding transcript
with a complete open reading frame. We found that 18 of
these 30 RFX TSS locations matched Ensembl protein-
coding transcripts. The remainder (12) of the 30 RFX TSS
locations were treated as novel transcript isoforms in human
tissues. We selected seven of these as representatives for ex-
perimental validation by RT-PCR and sequencing (Table 1,
Additional file 3: Table S1). The seven novel transcripts con-
sist of (i) testis specific pC@RFX1 and pE@RFX3, (ii)
broadly expressed and highest in brain pC@RFX3,
pC@RFX5, pA@RFX7, pC@RFX7, and (iii) lowly expressed
pA@RFX8.
Next, we assessed the full transcript sequences (from
5′ to 3’ UTRs) including their coding potential (from
start to stop codons) from both the matched Ensembl
protein-coding transcripts and the novel sequence-
verified transcripts (Table S2 in Additional file 2). Repre-
sentatives of the RFX1–8 transcripts are shown in Fig. 1a.
We found that the majority of RFX transcript isoforms
originating from the same gene encode identical proteins
suggesting that tissue and cell type specificity arises
mainly from differences in TSS architecture and
Table 1 RFX1–8 expression data and novel transcripts





RFX1 (chr19) pA@RFX1 ENST00000254325 Broad Cerebellum (brain)
pB@RFX1 ENST00000254325
pC@RFX1* Novel transcript* Specific Testis
RFX2 (chr19) pA@RFX2 ENST00000303657 Broad Uterus
pB@RFX2 ENST00000303657 Testis
pC@RFX2 ENST00000303657 Medulla oblongata (brain)
RFX3 (chr9) pA@RFX3 ENST00000382004 Broad Cerebellum (brain)
pB@RFX3 ENST00000382004 Lung, fetal
pC@RFX3* Novel transcript* Cerebellum (brain)
pD@RFX3 ENST00000382004 Lung, fetal
pE@RFX3* Novel transcript* Specific Testis
RFX4 (chr12) pA@RFX4 ENST00000392842 Specific Spinal cord
pB@RFX4 ENST00000229387 Specific Testis
pC@RFX4 ENST00000357881
RFX5 (chr1) pA@RFX5 ENST00000290524 Broad Blood (immune system)
pB@RFX5 ENST00000290524 Tonsil (immune system)
pC@RFX5* Novel transcript* Brain, fetal
pD@RFX5 Novel transcript Duodenum, fetal (GI)
RFX6 (chr6) pA@RFX6 ENST00000332958 Specific Duodenum, fetal (GI)
pB@RFX6 ENST00000332958
pC@RFX6 ENST00000332958




RFX8 (chr2) pA@RFX8* Novel transcript* Lowly expressed (TPM < 5) Thymus (immune system)
pB@RFX8 ENST00000428343 Medial frontal gyrus (brain)
pC@RFX8 Novel transcript Noise (TPM < 1) Heart
pD@RFX8 Novel transcript Breast
pE@RFX8 Novel transcript Rectum, fetal
Thirty TSS locations from eight human RFX genes and their respective tissue profile summaries are presented (cf. Methods; GI = gastrointestinal tract). For an
expanded summary and the analysis of functional domains, see Tables S1 and S2 in Additional file 3, respectively. Novel transcripts are marked in bold and those
selected for experimental validation are marked with an asterisk. For RT-PCR verified sequences of novel transcripts, see Table S9 in Additional file 3
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regulation through their corresponding promoters. The
exceptions are RFX1, RFX4 and RFX8 with isoforms en-
coding different protein variants. The testis specific
pC@RFX1 transcript isoform encodes a shortened N-
terminal region upstream of the activating domain (AD).
RFX4 transcript isoforms have been extensively studied
[43–45] and thus complement our results, where we
found isoforms encoding different RFX4 protein vari-
ants. The RFX8 gene encodes a TF protein lacking a
DNA binding domain (DBD) (ENSP00000401536,
www.ensembl.org). Here, we experimentally validated
RFX8 transcripts by sequencing cDNA from human
brain total RNA and uncovered novel splicing patterns
leading to alternative RFX8 protein variants, with and
without DBD (Table S1 in Additional file 3).
RFX functional domain composition is independent of
expression profile
Human RFX TFs were previously categorized through
phylogenetic analysis of their four functional domains
outside the DBD: activating domain (AD), domain B,
domain C and dimerization domain (DIM) [9, 10, 16].
Given the variation in coding potential of all 30
RFX1–8 transcript isoforms, we investigated whether
there is a correlation between the presence or ab-
sence of certain RFX functional domains and the
CAGE TSS expression profiles in human tissues. First,
we categorized all RFX1–8 transcripts into four
groups based on their functional domain structure: (i)
Group 1: RFX1–3 with all known domains, (ii) Group
2: RFX4, RFX6 and RFX8 lacking the AD, (iii) Group
3: RFX5 and RFX7 with only the DBD, (iv) Group 4:
RFX4 and RFX8 lacking the DBD (Fig. 1a). When we
then compared these four groups to their respective
TSS expression profiles, we did not find any indica-
tion that RFX TFs with similar domain composition
would be expressed broadly or specifically in a certain
tissue cluster, suggesting that the RFX functional do-
main composition is independent of expression pro-
file. We analyzed RFX4 and RFX8 in more detail to
illustrate this point (Fig. 1b, c).
Based on the FANTOM5 expression profiles, the gene
RFX4 is highly tissue specific compared to other RFX
genes. In our analysis, we connected three RFX4 TSS
a
b c
Fig. 1 Representative RFX transcripts grouped according to their functional domain compositions. a Representative RFX transcripts (to scale in nucleotides /
nt) can be categorized based on the presence or absence of functional domains. Group 1 consists of RFX1, RFX2, and RFX3, which have all the domains.
Group 2 consists of RFX4, RFX6 and RFX8, which have all domains but the AD. Group 3 consists of RFX5 and RFX7, which have only the DBD. Group 4 is
novel, consisting of isoforms of RFX4 and RFX8, which lack the DBD. The start of the black bar marks the TSS position. Green and red arrows mark start and
stop codon positions, respectively. The RFX protein domains encoded by these transcripts are AD (activation domain), DBD (DNA binding domain), B
(domain B), C (domain C), and DIM (dimerization domain). They are indicated using color-coded boxes. The DBD (red box), which typically spans 222–225 nt
(cf. Table S2 in Additional file 3) serves as a size marker. b, c RFX4 and RFX8 TSS locations illustrate best that RFX functional domain composition is
independent of expression profile. They are connected to Ensembl protein-coding transcripts or shown as novel, validated transcripts (in red). Exon numbers
refer to those in the corresponding Ensembl transcript IDs (distance and positions are not to scale). pA@RFX4 (red) belongs to the brain and spinal cord
cluster, whereas pB and pC@RFX4 (green) belong to the testis cluster (cf. Additional file 2). The highest expressed tissues for pA and pB@RFX8 are thymus
and medial frontal gyrus, respectively, and they are not color-coded because of their low expression levels in tags per million (TPM< 5) (Table 1)
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locations to three different Ensembl protein-coding
transcripts (Fig. 1b). The longest, highest expressed
transcript falls into Group 2 (lacking the AD); it is spe-
cifically expressed in the brain and spinal cord. The
other two less expressed transcripts are both testis spe-
cific, whereby one belongs to Group 2 (lacking the AD)
and the other one to Group 4 (lacking the DBD). The
newly described gene RFX8 is the least expressed of all
the RFX genes. We connected the two highest expressed
RFX8 TSS locations with three possible transcripts (Fig.
1c). The same TSS can lead to different transcripts en-
coding protein variants, which either fall into Group 2
(lacking the AD) or Group 4 (lacking the DBD), sug-
gesting an additional layer of gene regulation on top of
the TSS architecture itself. Interestingly, RFX8 tran-
scripts with DBD revealed that the RFX8 DBD is slightly
shorter than the DBDs in RFX1–7. Whereby, multiple
sequence alignments of RFX DBD amino acid sequences
reveal that it is the least conserved N-terminal amino
acids of the DBD that are missing in RFX8 (Figure S1 in
Additional file 3).
Tissue and cell type specific clustering of RFX family
members with the target genes they regulate
To correlate and eventually predict which RFX family
member regulates which target gene in which human tis-
sue and cell type, we compared and clustered the expres-
sion profiles of all RFX family members with direct RFX
target genes. We selected from the literature a large num-
ber of validated direct RFX target genes in humans, as
demonstrated either by a biochemical interaction between
an RFX TF and the respective X-box promoter motif or
by confirmation of the X-box function by mutation ana-
lysis (Table S3 in Additional file 3). We then extracted the
CAGE TSS expression values (TPM) of these genes from
the FANTOM5 database and performed unsupervised
heat map clustering based on the correlations of expres-
sion values across 135 tissue types (Fig. 2).
We identified strong tissue specific RFX and target
gene clusters, namely for testis (RFX1–4 and target
genes GPR56, ALMS1, RFX1) and the gastrointestinal
tract (RFX5–6 and target gene INS/insulin). We also ob-
served strong differences between clusters of the
Fig. 2 Heat map of tissue expression clusters of RFX1–8 and their experimentally confirmed target genes in humans. Heat map of
unsupervised hierarchical clustering of 30 TSS locations of RFX genes and 185 TSS locations of validated RFX target genes (with
shorthand p for promoter) based on the expression values in tags per million (TPM) across 135 human tissue samples extracted from
FANTOM5. The heat map color-code represent Pearson correlation values with a gradient of − 1 in dark blue/blue (negative correlation), 0 in white
(zero correlation) and 1 in yellow/orange (positive correlation). The graph was generated by the heatmap.2::gplots [95] R package. RFX TSS locations
tissue clusters (y-axis) are color-coded as described in Additional file 2. The tissue cluster divisions of RFX target genes (x-axis) are based on groups of
tissues with the highest expression values (TPM) of the respective TSS locations. The term “other tissues” includes adipose, kidney, lung, seminal vesicle,
skeletal muscle, throat and uterus
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immune system (RFX5) and the brain (RFX1, 3, 4, 7).
This underscores that (i) the respective RFX family
members regulate different sets of target genes as they
are not co-expressed in a given tissue type, and (ii) for a
given target gene RFX TFs can act as activators or as in-
hibitors. For brain tissue and cell types, RFX1, 3, 4 and 7
clustered tightly together, indicating a preference for
these RFX family members to (co-) regulate the expres-
sion of brain-specific genes such as the ciliopathy/
Alström syndrome gene ALMS1, the dyslexia candidate
gene KIAA0319 or the gene MAP1A. Interestingly, an-
other member of the brain cluster, pC@RFX2 (Table 1,
Additional file 2), in the context of target genes clus-
tered separately (Fig. 2), suggesting that in the brain
RFX2 regulates a distinct set of target genes. Alterna-
tively, RFX2 may interact with other RFX family mem-
bers or other co-factors without preference as long as
they are co-expressed in a given tissue and cell type.
X-box motif positioning in the human genome
RFX TFs regulate their target genes by binding to a
conserved X-box motif in the promoter region. Previ-
ous X-box motif searches have typically been carried
out using 1–3 kb sequence windows upstream of the
TSS or ATG, such as in C. elegans [27], D. melanoga-
ster [23], mouse and human [46]. To our knowledge,
precise X-box motif positioning has not been character-
ized in the human genome. Thus, we determined the most
likely positioning of functional X-box motifs in the pro-
moter region, defined as 5000 bp upstream (− 5000) and
2000 bp downstream (+ 2000) in relation to TSS locations,
of experimentally validated human RFX target genes.
To facilitate the search, we used two curated TF binding
profiles for human RFX available in the JASPAR (2018)
database [47]: RFX2 (MA0600.1) and RFX5 (MA0510.1)
(Table S4 in Additional file 3). As a control, we selected a
10-fold larger random set of TSS locations across the hu-
man genome. Our search effort revealed that X-box hits
are typically located very close to RFX target genes TSS lo-
cations (Fig. 3, Table S5 in Additional file 3). Based on
search and find statistics the X-box positioning window
can be further subdivided into a robust window of − 500
to + 500 bp and a permissive window of − 2300 to +
1400 bp. Using an independent search approach (the
MEME suite FIMO software) [48] we confirmed these
overall search and find parameters for human X-box
motifs. Our analysis enhances the prediction power of
future searches for functional X-box motifs, which re-
lates to both upstream and downstream of TSS loca-
tions of candidate human RFX target genes and
pinpoints their likely locations. Functional X-box mo-
tifs at larger distances from TSS locations (e.g at dis-
tal enhancers) are likely to be the exception rather
than the norm (Table S6 in Additional file 3).
Prediction of upstream RFX regulators using transcription
factor binding site (TFBS) analysis
Identifying the upstream regulators of RFX genes will allow
predicting the developmental and cellular niche that RFX
TFs occupy. Thus, we searched for TF binding profiles
over-represented in the promoter and enhancer regions of
all 8 human RFX genes. We used search windows of −
5000 to + 2000 bp in relation to 30 RFX TSS locations and
- 200 to + 200 bp around the midpoints of 13 significantly
correlated candidate RFX enhancer sequences (extracted
from Andersson et al. [49]; Table S7 in Additional file 3).
We then scanned these regions with all the core vertebrate
TF binding profiles present in the JASPAR 2016 database
[47]. The enrichment for TF binding profiles was assessed
against a 10-fold larger random set of human promoter
and enhancer regions using the oPOSSUM3 tool [50].
We identified 19 over-represented TF binding profiles
(Fig. 4) associated to the TFs SP2 (specificity protein 2) (JAS-
PAR profile MA0516.1), E2F4 (E2 factor 4) (MA0470.1),
KLF16 (Kruppel like factor 16) (MA0741.1), SP8 (specificity
protein 8) (MA0747.1), SP3 (specificity protein 3)
(MA0746.1), EGR3 (early growth response 3) (MA0732.1),
ESR1 (estrogen receptor alpha) (MA0112.3), Creb5 (cAMP
responsive element binding protein 5) (MA0840.1), ZNF740
(zinc finger protein 740) (MA0753.1), ATF7 (activating tran-
scription factor 7) (MA0834.1), SOX21 (sex determining re-
gion Y-box 21) (MA0866.1), MZF1 (myeloid zinc finger 1)
(MA0056.1 and MA0057.1), Tcfl5 (transcription factor like
Fig. 3 X-box motif position with respect to TSS locations. Density
frequency of X-box motif positions with respect to the TSS
locations of experimentally proven direct RFX target genes in
humans (shown in blue) and a set of 10× random TSS locations
from FANTOM5 (shown in red): TSS -5000 to + 2000 bp windows
were scanned with two JASPAR RFX motifs (RFX2 MA0600.1 and
RFX5 MA0510.1) with 80% threshold. We define a sequence
window as “robust” by the area where the two curves with 95% C.I.
smoothing do not overlap. We define a sequence window as
“permissive” by the area where the two curves intersect
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5) (MA0632.1), KLF5 (Kruppel like factor 5) (MA0599.1),
SP1 (specificity protein 1) (MA0079.3), EGR1 (early growth
response 1) (MA0162.2), TFAP2C (transcription factor AP-2
gamma) (MA0815.1) and JDP2 (Jun dimerization protein 2)
(MA0656.1). The full list of the TF binding profiles can be
found in Additional file 4.
siRNA validation of RFX regulators
To test if any of the over-represented TF binding profiles
can be linked to functional upstream regulation of RFX
genes, we selected two TFs within the high-scoring TF
binding profiles. We used siRNA knockdown of SP2 and
ESR1 followed by qRT-PCR measuring the fold change of
mRNA expression levels of RFX genes. We could success-
fully demonstrate knockdown of SP2 and ESR1 both at the
mRNA level by qRT-PCR and at the protein level by
immunoblotting (Fig. 5). The TF binding profiles of SP2
and ESR1 both scored clearly above the z-score threshold
(Fig. 4). We selected the human MCF7 breast cancer cell
line for which data are available in FANTOM5. In this cell
line the genes SP2, ESR1, RFX1–3, − 5, and − 7 are
expressed sufficiently high (TPM> 5), while the genes
RFX4, − 6 and − 8 are not expressed (TPM= 0). We used
efficiency-adjusted fold change quantification against scram-
bled (Scr) control siRNA normalized to the geometric mean
of HPRT1 and HSPCB as two independent reference genes
[51]. All the Ct levels of the test siRNA and Scr control
siRNA can be found in Additional file 5.
We observed that siRNA knockdown of SP2 and ESR1
in human MCF7 cells resulted in a significant fold change
in the mRNA expression levels of at least one of the RFX
genes (Fig. 5). siRNA knockdown of SP2 resulted in both
activating and inhibiting effects on RFX genes, whereby
only RFX7 showed significant up-regulation. In contrast,
siRNA knockdown of ESR1 revealed consistent inhibitory
effects on all the RFX genes analyzed, with RFX2, − 3, − 5,
and − 7 being significantly up-regulated. These data show
that computational TFBS analyses of the promoter regions
of RFX1–8 correctly identified functional upstream regu-
lators of these RFX genes. Depending on the individual
RFX gene these upstream regulators act either as activa-
tors or as repressors.
Discussion
We have exhaustively analyzed all eight members of the
human RFX TF gene family (RFX1–8). By extracting and
computationally analyzing large-scale experimental data
sets, we were able to describe in detail RFX gene expres-
sion as well as the RFX gene regulatory landscape in
many different human tissues and cell types, including
Fig. 4 TF binding profiles in the promoter and enhancer regions of RFX genes. Distribution of all the z-scores of all the core vertebrate transcription
factor binding site (TFBS) profiles in JASPAR 2016, with the search areas consisting of − 5000 to + 2000 bp with respect to the 30 RFX TSS locations and
− 200 bp to + 200 bp from the mid-points of the RFX enhancers, against a background of a set of 10× random TSS locations and enhancers with
identical window size and matching %GC distribution from FANTOM5. High-scoring or over-represented TF binding site profiles were computed as
having z-scores above the mean + 2 x standard deviation (red dotted line)
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in parts the experimental validation thereof. We provide
the first detailed experimental characterization of RFX8
and of RFX isoforms without DBD. Further, we provide
insight into upstream regulators of human RFX genes
and determined the sequence windows in which – in
most cases – human RFX TFs act as direct regulators of
their target genes. Thereby we provide an in-depth cata-
logue and key resource for future work on the roles that
RFX TFs play in human development and disease.
Our extensive survey of all the human RFX (1–8) gene
expression profiles enabled us to carefully analyze all the
transcript isoforms and determine the potential protein
variants encoded by these isoforms. We ordered all ex-
pression profiles from low to high, from broad to tissue
specific, made tissue and cell type assignments, includ-
ing isoform correlations and non-correlations, and
thereby were able to cluster the expression profiles for
all the isoforms of all the human RFX genes. We found
and experimentally validated that – typically – RFX gene
TSS locations (of the same gene) would lead to the same
protein variant, suggesting that it is mostly promoter
and TSS architecture that gives rise to diversity in gene
expression profiles. These results highlight the import-
ance of studying non-coding regulatory regions of key
genes involved in developmental processes such as cell
type specification and differentiation. Exceptions include
TSS locations for the gene RFX4 that were spread across
a large genomic distance leading to transcript isoforms
encoding different tissue specific protein variants.
Our work lead to an updated grouping of human RFX
TFs and showed that RFX functional domain compos-
ition is independent of expression profile. We identified
two RFX genes, RFX4 and RFX8, which can encode pro-
tein variants without DBD. The function of RFX protein
variants without DBD is unclear. Possibly, they act as
tissue-specific co-repressors, similar to SHP proteins
[52]. This potential role is clearly inferred for RFX4,
where such competitive co-repression may occur in the
testis but not in the nervous system [44]. Transcript val-
idation for the newly described gene RFX8 revealed the
possibility for encoding protein variants with and with-
out a DBD. For the protein variant with DBD, this do-
main would be slightly shorter as it is missing the least
conserved N-terminal 20 amino acids. In addition to the
overall low expression level of RFX8, it raises the ques-
tion of RFX8 functionality. RFX8 was most prominently
expressed in Schwannoma cells, suggesting a role for
RFX8 in Schwann cell proliferation.
Given the central role that RFX TFs play during develop-
ment (e.g. in the differentiation of cilia), we were interested
in finding candidate upstream regulators of RFX genes. We
used computational predictions based on over-represented
TF binding profiles to find candidate upstream regulators
of RFX genes and thereby infer the developmental path-
ways that RFX1–8 are part of. The over-represented TF
binding profiles that our analysis uncovered are associated
with TFs involved in (i) neural development (SP2, ESR1,
Creb5, SOX21) [53–56] and neurite outgrowth (KLF16,
EGR3) [57, 58], (ii) cognitive functions (EGR3, EGR1) [59],
(iii) craniofacial development (SP8) [60], (iv) proliferation
of immune cells (EGR3, KLF5) [61, 62], platelet formation
(SP3, SP1) [63] and innate immunological memory (ATF7)
[64], (v) cell cycle control (E2F4) [65, 66] and tumor sup-
pression (ZNF40, MZF1, TFAP2C, JDP2) [67–70], and (vi)




Fig. 5 siRNA validation of candidate RFX regulators. The genes SP2 and
ESR1 represent the high-scoring group of candidate RFX regulators (cf.
Fig. 4 and Additional file 4). In the MCF7 breast cancer cell line,
amplification efficiency-adjusted mRNA fold change quantifications of
RFX1, 2, 3, 5 and 7 were normalized to the geometric mean of HPRT1 and
HSPCB, whereby a fold change equaling 1 describes an unchanged
expression level. For this we used (a) SP2 siRNA versus scrambled (Scr)
control siRNA knockdown, and (b) ESR1 siRNA versus scrambled (Scr)
control siRNA knockdown. In (a, b) error bars represent SEM and fold-
change statistical significance was calculated using the student two-
sample t-test (***p-value ≤0.01, **p-value ≤0.05, *p-value ≤0.1). a, c SP2
siRNA knockdown was confirmed at both the mRNA and protein level
and a significant up-regulation of RFX7 and down-regulation of RFX5 were
observed. b, c ESR1 siRNA knockdown was confirmed at both the mRNA
and protein level and significant up-regulations of RFX2, 3, 5 and 7 were
observed. c Immunoblotting band intensities were quantified using
ImageJ and normalized with the indicated loading controls
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profiles for RFX TFs themselves were not over-represented,
suggesting that autoregulation is not a common feature for
the expression of RFX1–8 genes and that RFX1 autorepres-
sion may be the only exception [72].
We validated SP2 and ESR1 by siRNA knockdown and
qRT-PCR and found that they act as inhibitors of the
RFX genes. We assume that these candidate upstream
regulators act directly, given the over-representation of
their TF binding site profiles in RFX1–8 promoter and
candidate RFX enhancer regions. The cellular context
we used for experimental validation, human MCF7
breast cancer cells, very likely does not represent all hu-
man tissues. Thus, more exact mechanisms of RFX gene
regulation remain to be analyzed in different cell-type
specific environments. At present, there is little evidence
for preferences in RFX dimerization patterns [43].
The discovery of new RFX target genes typically starts
with searching for X-box motifs, the binding site for RFX
TFs. X-box searches have mostly focused on upstream pro-
moter sequences, e.g. upstream of the first exon or of the
ATG [23, 27, 73]. Here we expand by relating X-box pos-
ition to both upstream and downstream of human gene
TSS locations. X-box position, motif sequence and conser-
vation across species (cf. Henriksson et al. [74]) allow for a
precise ranking of hits. With respect to a given gene TSS
location we have assigned these hits to a permissive win-
dow (− 2300 to + 1400) and a robust window (− 500 to +
500) for the higher ranks. Our data strengthen and surpass
previous work in other organisms where functional X-box
motifs were found close to the gene start sites [75]. Our
type of analysis will enhance the prediction power of future
searches for functional X-box motifs, because relating X-
box motifs to both upstream and downstream of TSS loca-
tions of candidate human RFX target genes adds another
level of precision to the search procedure. Functional X-
box motifs at larger distances from TSS locations (e.g at
distal enhancers) are likely to be the exception rather than
the norm. The presence of X-box motifs was shown to
contribute to the activeness of both promoters and en-
hancers, whereby distal enhancers that harbor X-box mo-
tifs exhibited greater promoter activity than enhancers that
lack them [76]. This phenomenon would fit a model where
(as found in Xenopus leavis) Rfx2 and Foxj1 coordinately
regulate ciliary gene expression, with Rfx2 stabilizing Foxj1
binding at chromatin loops [77].
Comparative tissue and cell type specific expression pro-
file clustering represents a complementary approach to X-
box searches for the ascertainment of cross-connections
between RFX genes and candidate sets of downstream tar-
get genes. We have used this approach successfully to de-
scribe the key roles that defined RFX family members play
by regulating only certain target genes in e.g. human testis
and the gastrointestinal tract. Combining both methods, X-
box searches and expression profile clustering, will be very
helpful for the discovery of precise sets of RFX target genes
in many different human tissue and cell types.
Studies in mammals suggest that RFX TFs function in
terminal cell differentiation or in the maintenance of
certain functional specializations. Examples include the
differentiation and maintenance of pancreatic β-cells as
insulin producers [78], the repression of collagen forma-
tion during adult life [79], the maintenance of testis cord
integrity [80], the regulation of spermiogenesis and
sperm flagellum assembly [17], the maintenance of post-
natal auditory hair cells [81], and the regulation of ciliary
genes involved in the assembly and maintenance of
functional cilia [16]. Interestingly, RFX TFs seem to
exert their function on structures connected to polarized
cell surfaces, e.g. cilia, immune synapse, neuronal syn-
apse and the vascular face of β-cells [82].
Given such a range of RFX TF functions in different tis-
sue and cell types, elucidating their role in disease will be
facilitated when more precise connections can be estab-
lished between specific RFX protein isoforms, RFX target
gene sets and quantity or cell type of expression. So far only
RFX5 and RFX6 mutations have been linked to defined dis-
eases, while mutations in other RFX genes may cause more
complex, pleiotropic disease symptoms. Embryonic lethality
in Rfx1−/− mice suggests that Rfx1 function cannot be com-
pensated for [83]. RFX mutations may cause ciliopathies, as
RFX TFs directly regulate many ciliary genes in different
cell and tissue types. The complexity of ciliopathies arises
due to primary cilia being present on most human cell
types [84]. Very recently, X-box motifs were shown to over-
lap with type 2 diabetes risk alleles [85], elevating the im-
portance of understanding X-box motif sequence and
position, and X-box containing promoter activity in con-
nection to RFX target gene regulation.
Our exhaustive and in-depth characterization of the
functional domain composition and the expression pro-
files of all the eight human RFX genes, including upstream
regulatory and downstream target gene analysis, in con-
nection with mammalian studies, e.g. investigating Rfx
mice mutants, will serve as the basis for uncovering and
understanding phenotypes or pathologies of RFX muta-
tions in humans. For example, one might expect male
sterility to be associated with mutations in testis specific
RFX1–4 gene isoforms, or with dys-regulation of testis
specific RFX target genes (e.g. GPR56 [86], ALMS1 [87]
and RFX1), or with the role upstream RFX regulators (e.g.
ESR1 [88, 89]) play in ciliogenesis.
Conclusions
We provide a comprehensive and systematic
characterization of the expression profiles of all the eight
human RFX genes, including the previously undescribed
RFX8. We open the window to their potential upstream
regulators during development. We advance on how
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human RFX TFs regulate their target genes. Thereby,
our study contributes to the understanding of the differ-
ent functions for RFX TFs in their specific spatial and
temporal context in the different tissue and cell types of
humans. Our work will greatly help in uncovering their
cell-type specific target gene batteries, essential for eluci-
dating RFX-associated aspects of cellular specialization
and terminal functional differentiation. In turn, this will
aid in understanding disease mechanisms and outcome.
Methods
Extraction and analysis of CAGE TSS locations from the
FANTOM5 database
CAGE TSS locations and expression profiles were extracted
from FANTOM5 Phase I as downloaded from SSTAR [90]:
http://fantom.gsc.riken.jp/5/sstar/Main_Page. FANTOM5
TSS data represent expression profiles from 889 biological
samples with assigned detection levels in arbitrary units
“tags per million” (TPM) [33]. We categorized all samples
into three separate groups: human tissues (135 samples –
80% adult and 20% fetal), human primary cells (170 samples
– here represented as the average of the donor replicates)
and human cell lines (255 samples), and excluded the time
course samples. TSS data were extracted and analyzed, and
then named with shorthand p (for promoter) in alphabetical
order (pA, pB, pC, etc.) based on the following criteria: (1)
if the tissue correlation is equal to or greater than 0.7 and
individual TSS locations fall within 100 bp of each other,
they were merged into one TSS; (2) if the highest tissue
sample TPM is < 1, this TSS was disregarded unless the
highest primary cell (in any donor replicate) or cell line
TPM is ≥5; (3) the alphabetical order of TSS locations is
based on the descending order of its total sum of TPM
values in all 889 biological samples after conditions (1) and
(2) are met.
A given TSS location is considered as being expressed
broadly if it is expressed at TPM> 5 in a large number and
variety of tissues (n > 10). Conversely, a given TSS location
is considered as being expressed specifically if it is
expressed at TPM> 5 in a small number of tissues of the
same organ (n < 10). The exceptions are: (i) pA of RFX4
displays high expression in many tissues (n > 10) but specif-
ically in the brain and spinal cord; (ii) RFX8 TSS locations
are either lowly expressed (TPM< 5) or at background
noise levels (TPM< 1). Additional information about these
and other CAGE TSS locations present in the FANTOM5
database (e.g. the presence or absence of TATA boxes, CpG
islands, etc.) has been described by Lizio et al. 2015 [90].
All the genomic coordinates are stated in BED format.
Transcript validation from novel TSS locations by RT-PCR
A given TSS location was deemed to be a novel tran-
script isoform for experimental validation when it does
not overlap with or is not found within +/− 50 bp of the
start site (indicated as exon 1) of known protein-coding
transcripts with complete open reading frame descrip-
tion in the Ensembl database (release 81 – July 2015,
http://www.ensembl.org/). We designed forward primers
to bind either within the novel TSS sequence, or over-
lapping with the 3′ end of the TSS, or at the most 50 bp
downstream from the TSS. Reverse primers were de-
signed to always bind downstream of the ATG, respect-
ively, from the reference Ensembl transcript. In the case
of the RFX8 gene, we designed additional primers that
sandwiched the DBD exonic region to confirm the pres-
ence or absence of a DBD-encoding exon. We reverse
transcribed 1 μg commercial human testis total RNA
(Clontech, Cat. No. 636533) and human whole brain
total RNA (Clontech, Cat No. 636530) using Invitrogen
SuperScript III First-strand Synthesis Super Mix for
qRT-PCR (Cat No. 11752–050). We used undiluted
cDNA and 40 PCR cycles with the exception of 45 PCR
cycles for RFX8. 2 μl of the PCR product were cloned
using a TOPO TA Cloning Kit (Invitrogen Dual Pro-
moter PCR II-TOPO Vector, Cat No. 450640). Then, 4–
10 white colonies from AMP + IPTG/X-gal plates were
screened by PCR M13 vector primers, out of which 2–4
independent samples were sequenced with T7 and SP6
universal primers. Sequencing results were analyzed
using the BLAT Tool (UCSC Genome Browser, http://
genome-euro.ucsc.edu/). In the case of the RFX8 DBD
transcript validation, at least 100 white colonies were
screened with PCR M13 vector primers prior to sequen-
cing, given the overall low expression of the RFX8 gene.
Sequences of primers and verified transcripts are listed
in Tables S8 and S9, respectively, in Additional file 3.
Determination of RFX protein domains
Peptide sequences of human RFX1–3 protein domains
(AD, DBD, B, C and DIM) as described previously [9, 10]
were used to determine the corresponding domains in hu-
man RFX4–8 using the T-coffee protein sequence align-
ment program [91] (http://www.tcoffee.org/). Visualization
of the RFX transcripts in Fig. 1a with the protein domain
composition was done using IBS software [92].
Positional X-box motif scanning
We scanned for candidate X-box motifs using two known
X-box motifs deposited in the JASPAR database [47]
(http://jaspar.genereg.net/): human RFX2 (motif MA0600.1,
representing a full-site X-box) and RFX5 (motif MA0510.1,
representing a half-site X-box). For these scans we used
DNA regions of 5000 bp upstream (− 5000) and 2000 bp
downstream (+ 2000) as search windows relative to the TSS
locations. We selected X-box motifs in the promoter re-
gions, which were captured by the JASPAR built-in scan
function (version 5.0_ALPHA) with an 80% threshold. Pre-
viously validated X-box motifs were found with these
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criteria and also independently using the MEME Suite
FIMO software (version 4.10.0) [48] (http://meme-sui-
te.org/tools/fimo) with a p-value < 0.0001. Positional motif
enrichment was ascertained by analyzing in the same way
10 times random TSS sets from all the CAGE TSS loca-
tions present in FANTOM5. The graphical smoothing
method employed was local polynomial regression fitting
(loess) constructed by the R package ggplot2::geom_smooth
[93] with a confidence interval (C.I.) level = 0.95.
Multiple TF binding profile analysis for the prediction of
candidate RFX regulators
We performed TF binding profile enrichment analyses using
the oPOSSUM3 tool [50] with the CORE vertebrate TF
binding profiles present in the JASPAR 2016 database [47].
DNA regions of − 5000 to + 2000 bp of the 30 RFX TSS lo-
cations and − 200 to + 200 bp from the midpoints of 13 can-
didate RFX enhancers were used as search windows
(foreground). Candidate RFX enhancers were chosen by
selecting enhancers present within − 500 kb to + 500 kb of
the 30 RFX TSS locations, as extracted from Andersson
et al. [49] (http://fantom.gsc.riken.jp/5/datafiles/latest/extra/
Enhancers/), and whose expressions were significantly corre-
lated (Spearman correlation with multiple testing correction,
False Discovery Rate < 0.05) with RFX TSS locations based
on FANTOM5 CAGE expression values (TPM) in 889
biological samples). As background we considered 10-fold
larger sets of DNA regions with %GC matching the ones of
the foreground sequences and derived for regions surround-
ing all phase 1.3 CAGE peak coordinates (http://fantom.gsc
.riken.jp/5/datafiles/phase1.3/extra/CAGE_peaks/hg19.cage_
peak_coord_permissive.bed.gz; − 5000 bp and + 2000 bp)
and phase 2.0 enhancer coordinates (http://fantom.gsc.riken
.jp/5/datafiles/phase2.0/extra/Enhancers/human_permissive
_enhancers_phase_1_and_2.bed.gz; +/− 200 bp) using Bias-
Away (https://www.ncbi.nlm.nih.gov/pubmed/24927817).
We computed the mean (m) and standard deviation (sd) of
the distribution of all the z-scores (considering the enrich-
ment of the total number of predicted TFBSs) obtained
from oPOSSUM3 and put a threshold at m + 2 x sd.
Validation of candidate RFX regulators by siRNA
knockdown and qRT-PCR
SP2 and ESR1 siRNA concentrations (Table S10 in
Additional file 3) were optimized for knockdown efficiency
(cutoff: more than 2-fold) using qRT-PCR. siRNA and
qPCR primer sequences (obtained from Eurofins Genom-
ics: https://www.eurofinsgenomics.eu/) were selected to tar-
get all the known protein-coding transcript isoforms.
Primer specificities were tested first by common PCR and
later by qPCR analyses of the melting curves using two
negative controls, a water sample and a cDNA sample
without reverse transcriptase. Sequences of qPCR primers
with their amplification efficiencies determined in a
standard control setup are listed in Table S11 in Additional
file 3. The MCF7 breast cancer cell line (Michigan Cancer
Foundation) was used as the human cell line listed in the
FANTOM5 database as having sufficiently high expression
of both the candidate and the RFX genes (TPM> 5). MCF7
cells were maintained using DMEM 1 g/L-D-glucose with
added pyruvate, 10% FBS, 1% Penicillin/Streptomycin and
1% L-glutamine at 37 °C at 5% CO2. Cells were seeded 24 h
prior to transfection (150,000 cells in 2 ml in a 6-well plate
format). Lipofectamine RNAiMAX (Invitrogen, Cat. No.
13778–030) was mixed with siRNA according to the manu-
facturer’s instructions. RNA was extracted (RNeasy Mini
Kit and DNase Set, QIAGEN) 24 h after transfection and
we used 2 biological replicates repeated on three different
days of transfection. We converted 1 μg RNA to cDNA
(Invitrogen SuperScript III First-strand Synthesis Super
Mix for qRT-PCR, Cat No. 11752–050). qPCR was per-
formed for 40 cycles in singleplex technical triplicates using
FastStart Universal SYBR Green Master with ROX refer-
ence dye (Roche Cat No. 04913914001) on an AB7500 Fast
machine. We used 2 μl of 1:3 diluted cDNA from a bio-
logical replicate in 10 μl total. Ct levels with automatic
threshold were obtained (Additional file 5) and efficiency-
adjusted fold-changes were calculated against scrambled
(Scr) control siRNA with the geometric mean of HPRT1
and HSPCB as two independent reference genes for
normalization [51]. Graph and statistical tests were per-
formed in R using the ggplot2 package [93] and two-tailed
one-sample Student’s t-test [94].
siRNA knockdown confirmation by immunoblotting
At 24 h after transfection with siRNAs, MCF7 cells were
collected and washed twice with PBS. Whole cell lysates
were prepared upon sonicating the cells in RIPA buffer
(Sigma-Aldrich, St. Louis, MO, USA) containing PMSF
(1 mM, final concentration) and a protease inhibitor cock-
tail (Sigma-Aldrich, St. Louis, MO, USA). The protein con-
tent of these cell lysates was determined using the BCA
protein assay kit (Thermo Scientific, Sweden). A total of
40–80 μg of protein was loaded per well, separated on a
12% SDS-PAGE gel (Bio-Rad, Stockholm, Sweden) and
transferred to a 0.45 μm pore-sized PVDF membrane (Bio-
Rad, Stockholm, Sweden). After transfer, membranes were
incubated overnight at 4 °C with primary antibodies (rabbit
polyclonal ESR1, Catalog # sc-543, dilution - 1:500, Santa
Cruz Biotech; rabbit polyclonal SP2 (A-8), Catalog # sc-
17,814, Lot # D0605, dilution - 1:100, Santa Cruz Biotech;
rabbit polyclonal beta-tubulin, Catalog # ab6046, dilution -
1:5000, Abcam; mouse monoclonal vinculin, clone V284,
Lot # 2627627, dilution - 1:5000, Millipore) diluted in 5%
milk. Subsequently, blots were washed and incubated with
either horseradish peroxidase-conjugated secondary anti-
body (polyclonal rabbit anti-mouse/HRP, Lot # 00054403,
dilution - 1:3000, Dako Chemicals) or Li-Cor donkey anti-
Sugiaman-Trapman et al. BMC Genomics  (2018) 19:181 Page 11 of 15
mouse IRDye 800CW (Catalog # 926–32,212, for vinculin)
or Li-Cor donkey anti-rabbit IRDye 680LT (Catalog # 926–
68,023, for ESR1) for 1 h at room temperature. Imaging
was performed using a Li-Cor Odyssey Fc system. An en-
hanced chemiluminescence technique (WesternBright Sir-
ius ECL substrate, Advansta) was applied for developing
the SP2 blot due to low abundance of the target protein. In
all other cases, fluorescence signals were acquired. Band in-
tensities were quantified using ImageJ and normalized with
the indicated loading controls.
Human reference sequence
The human reference sequence used is the Human Feb.
2009 (GRCh37/hg19) Assembly.
Additional files
Additional file 1: Detailed expression values (TPM) for RFX TSS locations.
Expression values in tags per million (TPM) for all 30 RFX TSS locations in
all 889 biological samples and their categorization into tissues (135),
primary cells (473 donor replicates and 170 merged replicates from the
average TPM value of the donor replicates), cell lines (255) and time
courses (26). (XLSX 355 kb)
Additional file 2: Hierarchical clustering, expression plots and top 10
tissues, primary cells and cell lines of RFX TSS locations. Hierarchical
clustering of 30 RFX TSS locations (with shorthand p for promoter)
based on expression values (TPM) across 135 human tissue samples,
using a 1-Pearson correlation distance measure and average linkage
method, as computed by the pvclust R package with nboot = 1000
with the numbers representing approximately unbiased (au) p-values
(Suzuki and Shimodaira, 2006). Tissue clusters are color-coded and
represent the groups of tissues with the highest overall expression
values: immune system (teal), gastrointestinal tract (purple), testis
(green), brain and spinal cord (red), and two minor clusters, uterus
and lung (black). RFX TSS locations without color code have low ex-
pression values (TPM < 5). This is followed by the expression profiles
of 30 RFX TSS locations in human tissues, primary cells and cell lines,
whereby for every one of the eight human RFX genes (1–8), summa-
rized TSS profile data are presented vertically (“top-down”), starting
with the a tissue plot, followed by a table of the top 10 tissues, a
table of the top 10 primary cells and a table of the top 10 cell lines
(highest expression levels are listed first, respectively). The tissue plot
is the expression level in log (base 10) TPM against tissues that are
sorted from the highest to the lowest expressed from 135 tissues,
whereby the plot only includes the first 100 tissues. The arbitrary unit
for detection of expression is tags per million (TPM) as defined by
FANTOM5. We consider TPM < 5 to be lowly expressed and TPM < 1
to be background noise. (PDF 3276 kb)
Additional file 3: Supporting tables, figures and supplementary
references. Table S1. Summary of RFX1–8 expression data and novel
transcript validation. Table S2. Positions of functional domains encoded
by RFX transcripts. Table S3. Experimentally proven, direct RFX target
genes in humans from the literature. Table S4. Human X-box motifs se-
lected from the JASPAR database. Table S5. Experimentally validated hu-
man X-box motif sequences in promoter regions that were captured by
the scanning criteria. Table S6. Experimentally validated human X-box
motif sequences that were either in distal regions or that were not cap-
tured by the scanning criteria. Table S7. RFX correlated enhancers within
+/− 500 kb of RFX TSS locations. Table S8. Primer sequences for novel
RFX transcripts validation. Table S9. Verified novel RFX transcript se-
quences. Table S10. siRNA sequences for candidate RFX regulators.
Table S11. qPCR primer sequences and amplification efficiencies for val-
idation of candidate RFX regulators. Figure S1. Human RFX1–8 DBD pro-
tein sequence alignment. Supplementary references. (DOCX 424 kb)
Additional file 4: Detailed candidate RFX regulator oPOSSUM3 scanning
results using JASPAR 2016 core vertebrate TF binding profiles.
Transcription factor binding sites (TFBS) scanning results from oPOSSUM3
within the promoter and enhancer regions of RFX1–8 using the CORE
vertebrate TF binding profiles in JASPAR 2016. Included are the DNA
regions that were considered as foreground and the following TF
binding site details: SP2 (specificity protein 2) (JASPAR profile MA0516.1)
and ESR1 (estrogen receptor alpha) (MA0112.3). (XLSX 50 kb)
Additional file 5: Ct levels of qRT-PCR, used for validation of candidate
RFX regulators by siRNA knockdown. Individual Ct levels with automatic
threshold obtained on an AB7500 Fast machine for SP2 and ESR1 as can-
didate RFX regulators and their respective test siRNA and scrambled (Scr)
control siRNA knockdown data on RFX genes (RFX1, RFX2, RFX3, RFX5,
RFX7) and the two reference genes (HPRT1, HSPCB). (XLSX 33 kb)
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